Straumann Holding AGXSWX:STMN +0.42%98 ROC (Joel Greenblatt) % is 12.59% as of Dec. 2025, which is 80% below its 10-year median of 63.25. GuruFocus rates XSWX:STMN with a GF Score™ of 98/100 and a GF Value™ of CHF136.92 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 840 Medical Devices & Instruments companies, Straumann Holding AG ranks better than 87.62% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Straumann Holding AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 12.59%.
The historical rank and industry rank for Straumann Holding AG's ROC (Joel Greenblatt) % or its related term are showing as below:
XSWX:STMN'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 16.76 Med: 63.25 Max: 110.22
Current: 45.29
During the past 13 years, Straumann Holding AG's highest ROC (Joel Greenblatt) % was 110.22%. The lowest was 16.76%. And the median was 63.25%.
XSWX:STMN's ROC (Joel Greenblatt) % is ranked better than 87.62% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 4.035
vs XSWX:STMN: 45.29
Straumann Holding AG's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 12.40% per year.
Straumann Holding AG (XSWX:STMN) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Straumann Holding AG ROC (Joel Greenblatt) % Related Terms
Straumann Holding AG ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Straumann Holding AG's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Straumann Holding AG ROC (Joel Greenblatt) % Chart
XSWX:STMN vs ISRG, BDX, MDLN: ROC (Joel Greenblatt) % Comparison
For the Medical Instruments & Supplies subindustry, Straumann Holding AG's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Straumann Holding AG ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Straumann Holding AG's ROC (Joel Greenblatt) % falls into.
Straumann Holding AG ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 12.59% mean?
Straumann Holding AG (XSWX:STMN) has a ROC (Joel Greenblatt) % of 12.59% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Straumann Holding AG and its competitors. This is 80% below median its historical median of 63.25. Over the past decade, Straumann Holding AG's ROC (Joel Greenblatt) % has ranged from 16.76 to 110.22. According to the industry distribution chart, Straumann Holding AG ranks #104 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 12.4%.
Is Straumann Holding AG's ROC (Joel Greenblatt) % too high?
Straumann Holding AG's current ROC (Joel Greenblatt) % of 12.59% is 80% below median its 10-year median of 63.25. Over the past 10 years, this metric has ranged from a low of 16.76 to a high of 110.22. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 4.04. Straumann Holding AG's value of 12.59% is 212% above this industry median. Based on the distribution chart, Straumann Holding AG ranks #104 out of 840 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Straumann Holding AG has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Straumann Holding AG's ROC (Joel Greenblatt) % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Straumann Holding AG ranks #104 out of 840 companies for ROC (Joel Greenblatt) %. This places Straumann Holding AG in the top 12% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.04. Straumann Holding AG's value of 12.59% is 212% above this benchmark. Historically, Straumann Holding AG's own ROC (Joel Greenblatt) % has ranged from 16.76 to 110.22 over the past decade. While the company's 10-year median is 63.25 vs. the industry median of 4.04, Straumann Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.04, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Straumann Holding AG's current ROC (Joel Greenblatt) % of 12.59% is 212% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Straumann Holding AG and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Straumann Holding AG's current ROC (Joel Greenblatt) % is 12.59%, which is 80% below median its own 10-year median of 63.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Straumann Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Straumann Holding AG (XSWX:STMN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF136.92, compared to a current price of CHF106.80 — trading 22% below its estimated fair value. The current ROC (Joel Greenblatt) % is 12.59%, which is 80% below median its 10-year median of 63.25 and 212% above the Medical Devices & Instruments industry median of 4.04. Straumann Holding AG's overall GF Score™ is 98/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Straumann Holding AG (XSWX:STMN), the current ROC (Joel Greenblatt) % is 12.59% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Straumann Holding AG (XSWX:STMN) Overvalued in 2026?
Based on GuruFocus' analysis, Straumann Holding AG stock appears to be undervalued.
The current stock price of CHF106.80 is trading 22% below its estimated GF Value™ of CHF136.92.
GuruFocus considers Straumann Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:STMN:
ROC (Joel Greenblatt) %: 12.59% (80% below median its 10-year median of 63.25)
GF Value™: CHF136.92 vs. price of CHF106.80 (22% below fair value)
Industry Position: 212% above the Medical Devices & Instruments median (#104 of 840)
No single metric tells the full story. See the XSWX:STMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The firm's core products are dental implants, and it holds over one third of the CHF 6 billion global market. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
98GF Score
Get the complete analysis for XSWX:STMN
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:STMN has been successfully added to your 
